Hepatitis C Treatment Eligibility in an Urban Population with and without HIV Coinfection

AIDS Patient Care and STDs

Volumn 18, Issue 4, 2004, Pages 239-245

  Adeyemi, Oluwatoyin M ^a,b,c   Jensen, Donald ^b   Attar, Bashir ^a,b   Ghaoui, Rony ^a   Gallagher, Maureen ^c   Wolen, Deborah ^c   Cotler, Scott J ^d  

^a Jr Hospital of Cook County   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c The CORE Center   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; RIBAVIRIN;

ADULT; ARTICLE; COMORBIDITY; CONTROLLED STUDY; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ILLNESS BEHAVIOR; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; SUBSTANCE ABUSE; TREATMENT CONTRAINDICATION; URBAN POPULATION;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; ELIGIBILITY DETERMINATION; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; ILLINOIS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT SELECTION; POLYETHYLENE GLYCOLS; POVERTY AREAS; RETROSPECTIVE STUDIES; RIBAVIRIN; STATISTICS, NONPARAMETRIC; URBAN HEALTH SERVICES;

EID: 2142768286     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/108729104323038919     Document Type: Article

References (18)

1. Sulkowski MS, Thomas DL. Hepatitis C in the HIV-infected person. Ann Intern Med 2003;138:197-207.
2. Soto B, Sanchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997;26:1-5.
3. Benhamou Y, Bouchet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology 1999;30:1054-1058.
4. Martinez-Sierra C, Arizcorreta A, Diaz F, et al. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 2003;36:491-498.
5. Darby SC, Ewart DW, Giangrande PLF, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. Lancet 1997;350:1425-1431.
6. Garcia-Samaniego J, Rodriguez M, Berenguer J, et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol 2001;96:179-183.
7. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001;32:492-497.
8. Soriano V, Garcia-Samaniego J, Bravo R, et al. Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Clin Infect Dis 2000;23:585-591.
9. Soriano V, Sulkowski M, Bergin C, et al. Care of patients with chronic hepatitis C and HIV co-infection: Recommendations from the HIV-HCV international panel. AIDS 2002;16:813-828.
10. Poynard T, Marcillin P, Lee SS, et al. Randomised trial of interferon alfa 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-1432.
11. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-1492.
12. Perez-Olmeda M, Nunez M, Romero M, et al. Pegylated IFN-α2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 2003;17:1023-1028.
13. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randornised trial. Lancet 2001;358:958-965.
14. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
15. Falck-Ytter Y, Kale H, Mullen KD, et al. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002;136:288-292.
16. Fleming CA, Craven DE, Thornton D, et al. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: Low eligibility for interferon treatment. Clin Infect Dis 2003;36:97-100.
17. Fultz SL, Justice AC, Butt AA, et al. Testing, referral, and treatment patterns for hepatitis C virus coinfection in a cohort of veterans with human immunodeficiency virus infection. Clin Infect Dis 2003;36:1039-1046.
18. Cacciola L Pollicino T, Squadrito G, et al. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999;341:22-26.